An interventional study of Neuralli Mood in Psychological Stress, Sleep Disturbance and Anxiety Symptoms, sponsored by Efforia, Inc. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by Efforia, Inc · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 96 studies in Burnout, Professional with a site in United States — 10 open to participants now, 16 under way, none of them phase 3. Burnout, Professional · United States.
Among the 96 studies in Burnout, Professional with a site in United States, this one is the 33rd largest by planned enrollment of the 89 interventional ones that give a count, is one of 2 that started in 2026, is one of 87 with no phase, reaches primary completion later than 10 of the 15 other live ones, and was the 95th registered.
216 studies on the registry are indexed under Burnout, Professional; 33 are open to participants now.
Browse Burnout, Professional studies →10 of the 96 studies in Burnout, Professional with a site in United States are open now. Recruiting first, the newest first:
Lancaster General Hospital · Sites in United States
Ages 25–70 · Healthy volunteers
University of Arkansas · Sites in United States
Ages 18+ · Healthy volunteers
Michelle Thompson · Sites in United States
Ages 18+ · Healthy volunteers
University of Michigan · Sites in United States
Ages 18+ · Healthy volunteers
Heather Ballard · Sites in United States
Ages 20–60 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Burnout, Professional studies recruiting now, 9 (64%) set no upper age limit and 5 (36%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
96 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 80 across 161 interventional studies indexed under Burnout, Professional.
Median enrollment 74 across the 89 interventional studies, 246 across the 7 observational. Of the 75 that completed or were terminated, 8 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 96 have an industry lead sponsor. The 10 most frequent:
Efforia, Inc is the lead sponsor of 25 studies on the registry; 20 are open to participants now.
Efforia, Inc has 1 study filed under Burnout, Professional — fewer than ten, so there is no comparison to draw.
7 of the studies in Burnout, Professional with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07221422Massachusetts General HospitalThe PREGNANT (Pregnant Resident Empowerment, GuidaNce, and Advocacy iN Training) Coaching Project | 2026-11-30 |
| NCT05942469Northwestern UniversityFostering Optimal Regulation of Emotion for Prevention of Secondary Trauma (FOREST) | 2026-12-31 |
| NCT03063372University of Mississippi Medical CenterPomegranate Supplementation and Well-Being Among Medical Students and Residents | 2027-02-01 |
| NCT05713669University of MichiganImpact of Resident Participation in Post-ICU Follow Up Clinic | 2027-04 |
| NCT07262372University of ArkansasSupervision in Substance Use Disorder Treatment Programs | 2027-05-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 96 studies in Burnout, Professional with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This decentralized, single-arm study evaluates the effects of 90 days of daily Neuralli Mood supplementation on perceived stress, sleep disturbance, mood, anxiety, depressive symptoms, happiness, and occupational burnout in adults experiencing stress or occasional sleep disruption. Participants serve as their own controls, completing validated self-report measures before beginning supplementation and again after the 90-day intervention, with safety and adherence check-ins during the study.
Neuralli Mood is a probiotic and postbiotic dietary supplement containing the proprietary gut-brain strains L. plantarum PS128 and heat-treated L. paracasei PS23. Participants take two capsules once daily, with or without food, at a consistent time for 90 days. Each two-capsule daily dose contains 30 billion CFU of L. plantarum PS128 and 20 billion heat-treated cells of L. paracasei PS23.
The study uses a prospective, open-label, single-group, within-participant design. Participants complete baseline assessments before the first dose and repeat the primary and secondary outcome assessments at the end of the 90-day supplementation period. Scheduled check-ins are used to assess adherence, tolerability, and adverse events.
The study is exploratory and is intended to generate preliminary evidence and individualized before-and-after information. Results will be interpreted in light of the absence of a concurrent control group, participant self-selection, expectation effects, and reliance on self-reported outcomes.
216 studies on the registry are indexed under Burnout, Professional; 33 are open to participants now.
This study's planned enrollment of 100 is above the median of 80 across 161 interventional studies indexed under Burnout, Professional.
Browse Burnout, Professional studies →Efforia, Inc is the lead sponsor of 25 studies on the registry; 20 are open to participants now.
Compared within Burnout, Professional, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stress, Psychological. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants take two capsules of Neuralli Mood once daily, with or without food, at a consistent time for 90 days and complete scheduled study assessments and safety check-ins.
Dietary Supplement: Neuralli Mood
Two acid-resistant capsules taken once daily for 90 days. Each daily dose contains 30 billion CFU of L. plantarum PS128 and 20 billion heat-treated cells of L. paracasei PS23. Other ingredients include microcrystalline cellulose, hypromellose, pectin, glycerol, silica, and magnesium stearate.
Also known as: Bened Life Neuralli Mood
Change in Depression Anxiety and Stress Scales-21 Stress Subscale Score
Change from baseline in the Stress subscale score of the Depression Anxiety and Stress Scales-21. Higher scores (maximum score of 42) represent greater severity of stress symptoms. (Minimum score of 0).
Time frame: Baseline before the first dose and end of the 90-day supplementation period
Change in PROMIS Sleep Disturbance Score
Change from baseline in the PROMIS Sleep Disturbance score. Higher scores (Maximum 40) represent greater sleep disturbance. Lower (Minimum 8) represent lower sleep disturbance.
Time frame: Baseline before the first dose and end of the 90-day supplementation period
Change in Depression Anxiety and Stress Scales-21 Anxiety Subscale Score
Change from baseline in the Anxiety subscale score of the Depression Anxiety and Stress Scales-21. Higher scores represent greater severity of anxiety symptoms. (minimum 0 to maximum 21)
Time frame: Baseline before the first dose and end of the 90-day supplementation period
Change in Depression Anxiety and Stress Scales-21 Depression Subscale Score
Change from baseline in the Depression subscale score of the Depression Anxiety and Stress Scales-21. Higher scores represent greater severity of depressive symptoms. (Minumum 0, maximum 21)
Time frame: Baseline before the first dose and end of the 90-day supplementation period
Change in Oxford Happiness Questionnaire Score
Change from baseline in the Oxford Happiness Questionnaire total score. Higher raw scores (max 174) represent greater self-reported happiness versus low scores (min 29).
Time frame: Baseline before the first dose and end of the 90-day supplementation period
Change in Burnout Assessment Survey Score
Change from baseline in the total score from the study's Burnout Assessment Survey, interpreted according to the instrument's scoring procedures. Raw Sum Minimum Score: 23 (Patient responds "Never" to every single item)Raw Sum Maximum Score: 115 (Patient responds "Always" to every single item)
Time frame: Baseline before the first dose and end of the 90-day supplementation period
Number of Participants With Treatment-Emergent Adverse Events
Number and proportion of participants reporting adverse events during supplementation, including gastrointestinal symptoms, allergic reactions, mood changes, sleep-related symptoms, discontinuations, and events requiring medical attention.
Time frame: From the first dose through completion of the 90-day supplementation period
Plan to share: Undecided — No individual participant data sharing plan has been finalized.
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Sep 2027, 14 months after the start.
Of 132 interventional studies with no phase under Burnout, Professional, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 14 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.